Saccharomyces boulardii Protease Inhibits the Effects of Clostridium difficile Toxins A and B in Human Colonic Mucosa

ABSTRACT Saccharomyces boulardii is a nonpathogenic yeast used in the treatment of Clostridium difficile diarrhea and colitis. We have reported that S. boulardii inhibitsC. difficile toxin A enteritis in rats by releasing a 54-kDa protease which digests the toxin A molecule and its brush border membrane (BBM) receptor (I. Castagliuolo, J. T. LaMont, S. T. Nikulasson, and C. Pothoulakis, Infect. Immun. 64:5225–5232, 1996). The aim of this study was to further evaluate the role of S. boulardii protease in preventing C. difficile toxin A enteritis in rat ileum and determine whether it protects human colonic mucosa from C. difficile toxins. A polyclonal rabbit antiserum raised against purified S. boulardii serine protease inhibited by 73% the proteolytic activity present in S. boulardii conditioned medium in vitro. The anti-protease immunoglobulin G (IgG) prevented the action of S. boulardiion toxin A-induced intestinal secretion and mucosal permeability to [3H]mannitol in rat ileal loops, while control rabbit IgG had no effect. The anti-protease IgG also prevented the effects ofS. boulardii protease on digestion of toxins A and B and on binding of [3H]toxin A and [3H]toxin B to purified human colonic BBM. Purified S. boulardii protease reversed toxin A- and toxin B-induced inhibition of protein synthesis in human colonic (HT-29) cells. Furthermore, toxin A- and B-induced drops in transepithelial resistance in human colonic mucosa mounted in Ussing chambers were reversed by 60 and 68%, respectively, by preexposing the toxins to S. boulardii protease. We conclude that the protective effects of S. boulardii onC. difficile-induced inflammatory diarrhea in humans are due, at least in part, to proteolytic digestion of toxin A and B molecules by a secreted protease.

[1]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[2]  C. Pothoulakis,et al.  Purification and properties of Clostridium difficile cytotoxin B. , 1986, The Journal of biological chemistry.

[3]  G. Corthier,et al.  Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. , 1986, Canadian journal of microbiology.

[4]  J. Hotz.  [Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study]. , 1990, Zeitschrift fur Gastroenterologie.

[5]  E. Wierbicki,et al.  Assay of proteolytic enzyme activity using a 14C-labeled hemoglobin. , 1971, Analytical biochemistry.

[6]  G. Corthier,et al.  Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. , 1990, Journal of general microbiology.

[7]  M. O'brien,et al.  Differential effects of Clostridium difficile toxins A and B on rabbit ileum. , 1987, Gastroenterology.

[8]  T. Gray,et al.  Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. , 1996, Gut.

[9]  L. Mcfarland,et al.  Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters , 1987, Antimicrobial Agents and Chemotherapy.

[10]  C. Pothoulakis,et al.  Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Pothoulakis,et al.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. , 1997, The American journal of physiology.

[12]  M. Delmée,et al.  Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. , 1993, Journal of pediatric gastroenterology and nutrition.

[13]  R. Tweten,et al.  Purification and characterization of toxin B from Clostridium difficile , 1988, Infection and immunity.

[14]  R Sedivy,et al.  Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.

[15]  S. Meyers.  Clostridium difficile Colitis , 1999, American Journal of Gastroenterology.

[16]  C. Pothoulakis,et al.  Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. , 1994, The Journal of clinical investigation.

[17]  G. Corthier,et al.  Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. , 1991, Canadian journal of microbiology.

[18]  M. Craynest,et al.  Response of Human and Rat Small Intestinal Mucosa to Oral Administration of Saccharomyces boulardii , 1986, Pediatric Research.

[19]  C. Pothoulakis,et al.  Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. , 1988, The Journal of clinical investigation.

[20]  A. Jarry,et al.  Early functional effects of Clostridium difficile toxin A on human colonocytes. , 1997, Gastroenterology.

[21]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[22]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[23]  A. Parodi,et al.  Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. , 1984, Arzneimittel-Forschung.

[24]  C. Pothoulakis,et al.  Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. , 1986, Gastroenterology.

[25]  C. Pothoulakis,et al.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. , 1993, Gastroenterology.

[26]  C. Pothoulakis,et al.  IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. , 1997, The American journal of physiology.

[27]  C. Pothoulakis,et al.  Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum , 1996, Infection and immunity.

[28]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[29]  C. Pothoulakis,et al.  Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. , 1991, The Journal of clinical investigation.

[30]  N. Sullivan,et al.  Purification and characterization of toxins A and B of Clostridium difficile , 1982, Infection and immunity.

[31]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.

[32]  G. Elmer,et al.  Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii , 1984, Antimicrobial Agents and Chemotherapy.

[33]  J. Bartlett,et al.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. , 1977, The Journal of infectious diseases.

[34]  B. McClane,et al.  The effects of Clostridium perfringens enterotoxin on morphology, viability, and macromolecular synthesis in vero cells , 1979, Journal of cellular physiology.